Skip to main content

Advertisement

SpringerLink
Log in

Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

It has been proposed that methylation signatures in blood-derived DNA may correlate with cancer risk. In this study, we evaluated whether methylation of the promoter region of the BRCA1 gene detectable in DNA from peripheral blood cells is a risk factor for breast cancer, in particular for tumors with pathologic features characteristic for cancers with BRCA1 gene mutations. We conducted a case–control study of 66 breast cancer cases and 36 unaffected controls. Cases were triple-negative or of medullary histology, or both; 30 carried a constitutional BRCA1 mutation and 36 did not carry a mutation. Blood for DNA methylation analysis was taken within three months of diagnosis. Methylation of the promoter of the BRCA1 gene was measured in cases and controls using methylation-sensitive high-resolution melting (MS-HRM). A sample with any detectable level of methylation was considered to be positive. Methylation of the BRCA1 promoter was detected in 15 of 66 cases and in 2 of 36 controls (OR 5.0, p = 0.03). Methylation was present in 15 of 36 women with breast cancer and without germline BRCA1 mutation, but in none of 30 women with breast cancer and a germline mutation (p < 0.01). The association between methylation and breast cancer was restricted to women with no constitutional BRCA1 mutation (OR 12.1, p = 0.0006). Methylation of the promoter of the BRCA1 gene detectable in peripheral blood DNA may be a marker of increased susceptibility to triple-negative or medullary breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ (1998) The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83:2335–2345

    Article  CAS  PubMed  Google Scholar 

  2. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat JP, Longy M, Guinebretière JM, Sauvan R, Noguchi T, Birnbaum D, Sobol H (1998) Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 58:1588–1592

    CAS  PubMed  Google Scholar 

  3. Iau PT, Marafie M, Ali A, Sng JH, Macmillan RD, Pinder S, Denley HE, Ellis IO, Wenzyck P, Scott N, Cross G, Blamey RW (2004) Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer. Breast Cancer Res Treat 85:81–88

    Article  CAS  PubMed  Google Scholar 

  4. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310–2318

    Article  CAS  PubMed  Google Scholar 

  5. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282–4288

    Article  PubMed  Google Scholar 

  6. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Bégin LR, Narod SA (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034

    Article  CAS  PubMed  Google Scholar 

  7. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Dopazo J, Rivas C, Benítez J (2005) Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90:5–14

    Article  CAS  PubMed  Google Scholar 

  8. Mavaddat N, Barrowdale D, Andrulis I (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prev 21:134–147

    Article  CAS  Google Scholar 

  9. Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P, Shelley Hwang E (2013) Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol 20:3254–3258

    Article  PubMed  Google Scholar 

  10. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9:444–450

    Article  CAS  PubMed  Google Scholar 

  11. Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A (2000) Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 21:147–151

    Article  CAS  PubMed  Google Scholar 

  12. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW (2000) Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21:1761–1765

    Article  CAS  PubMed  Google Scholar 

  13. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564–569

    Article  CAS  PubMed  Google Scholar 

  14. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI (2005) BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 65:10692–10699

    Article  CAS  PubMed  Google Scholar 

  15. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE (2006) Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 8:R38

  16. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60:5329–5333

    CAS  PubMed  Google Scholar 

  17. Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA (2005) High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 159:114–122

    Article  CAS  PubMed  Google Scholar 

  18. Seeber LM, van Diest PJ (2012) Epigenetics in ovarian cancer. Methods Mol Biol 863:253–269

    Article  CAS  PubMed  Google Scholar 

  19. Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE (2009) Methylation not a frequent “second hit” in tumors with germline BRCA mutations. Fam Cancer 8:339–346

    Article  CAS  PubMed  Google Scholar 

  20. Butcher DT, Rodenhiser DI (2007) Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours. Eur J Cancer 43:210–219

    Article  CAS  PubMed  Google Scholar 

  21. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL (2005) BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 91:179–186

    Article  CAS  PubMed  Google Scholar 

  22. Catteau A, Harris WH, Xu CF, Solomon E (1999) Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer correlation with disease characteristics. Oncogene 18:1957–1965

    Article  CAS  PubMed  Google Scholar 

  23. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrle W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Sauter G (2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med 44:539–548

    Article  Google Scholar 

  24. van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536

    Article  PubMed  Google Scholar 

  25. Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M (2010) BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 28:e563–e564

    Article  PubMed  Google Scholar 

  26. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ (2011) Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 103:334–346

    Article  CAS  PubMed  Google Scholar 

  27. Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M (2012) BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics 7:1225–1229

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Xu Y, Diao L, Chen Y, Liu Y, Wang C, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Deng D, Narod SA, Xie Y (2013) Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Ann Oncol 24:1498–1505

    Article  CAS  PubMed  Google Scholar 

  29. Ignatov T, Poehlmann A, Ignatov A, Schinlauer A, Costa SD, Roessner A, Kalinski T, Bischoff J (2013) BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC. Breast Cancer Res Treat 141:205–212

    Article  CAS  PubMed  Google Scholar 

  30. Hansmann T, Pliushch G, Leubner M, Kroll P, Endt D, Gehrig A, Preisler-Adams S, Wieacker P, Haaf T (2012) Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer. Hum Mol Genet 21:4669–4679

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S (2011) BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat 129:69–77

    Article  CAS  PubMed  Google Scholar 

  32. Al-Moghrabi N, Al-Qasem AJ, Aboussekhra A (2011) Methylation-related mutations in the BRCA1 promoter in peripheral blood cells from cancer-free women. Int J Oncol 39:129–135

    CAS  PubMed  Google Scholar 

  33. Kontorovich T, Cohen Z, Nir U, Friedman E (2009) Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Res Treat 116:195–200

    Article  CAS  PubMed  Google Scholar 

  34. Snell C, Krypuy M, Wong EM, Loughrey MB, Dobrovic A (2008) BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res 10:R12

    Article  PubMed Central  PubMed  Google Scholar 

  35. Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, Giles GG, Hopper JL, Dobrovic A (2011) Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) 4:23–33

    Article  CAS  Google Scholar 

  36. Chen Y, Toland AE, McLennan J, Fridlyand J, Crawford B, Costello JF, Ziegler JL (2006) Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer. Genet Test 10:281–284

    Article  CAS  PubMed  Google Scholar 

  37. Wojdacz TK, Thestrup BB, Overgaard J, Hansen LL (2011) Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events. Diagn Pathol 6:116

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Wojdacz TK, Thestrup BB, Cold S, Overgaard J, Hansen LL (2011) No difference in the frequency of locus-specific methylation in the peripheral blood DNA of women diagnosed with breast cancer and age-matched controls. Future Oncol 7:1451–1455

    Article  CAS  PubMed  Google Scholar 

  39. Wojdacz TK, Hansen LL, Dobrovic A (2008) A new approach to primer design for the control of PCR bias in methylation studies. BMC Res Notes 1:54

    Article  PubMed Central  PubMed  Google Scholar 

  40. Anjum S, Fourkala EO, Zikan M, Wong A, Gentry-Maharaj A, Jones A, Hardy R, Cibula D, Kuh D, Jacobs IJ, Teschendorff AE, Menon U, Widschwendter M (2014) A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Med 6:47

    Article  PubMed Central  PubMed  Google Scholar 

  41. Akbari MR, Lepage P, Rosen B, McLaughlin J, Risch H, Minden M, Narod SA (2014) PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst 106:djt323

    Article  PubMed  Google Scholar 

  42. Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, Rodrigues DN, Renwick A, Seal S, Ramsay E, Duarte Sdel V, Rivas MA, Warren-Perry M, Zachariou A, Campion-Flora A, Hanks S, Murray A, Ansari Pour N, Douglas J, Gregory L, Rimmer A, Walker NM, Yang TP, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Eccles D, Evans DG, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Gore M, Houlston R, Brown MA, Caufield MJ, Deloukas P, McCarthy MI, Todd JA, Breast and ovarian cancer susceptibility collaboration; Wellcome trust case control consortium, Turnbull C, Reis-Filho JS, Ashworth A, Antoniou AC, Lord CJ, Donnelly P, Rahman N (2013) Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 493:406–410

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Szwiec M, Jakubowska A, Górski B, Huzarski T, Tomiczek-Szwiec J, Gronwald J, Dębniak T, Byrski T, Kluźniak W, Wokołorczyk D, Birkenfeld B, Akbari MR, Narod SA, Lubiński J, Cybulski C (2014) Recurrent mutations of BRCA1 and BRCA2 in Poland: an update. Clin Genet. doi:10.1111/cge.12360

    Google Scholar 

  44. Lahiri DK, Schnabel B (1993) DNA isolation by a rapid method from human blood samples: effects of MgCl2, EDTA, storage time, and temperature on DNA yield and quality. Biochem Genet 31:321–328

    Article  CAS  PubMed  Google Scholar 

  45. Wojdacz TK, Dobrovic A (2007) Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 35:e41

    Article  PubMed Central  PubMed  Google Scholar 

  46. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, Villarreal-Garza C, González-Angulo AM, Bargalló E, Aguilar JL, Mohar A, Arrieta Ó (2011) Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 117:3658–3669

    Article  PubMed  Google Scholar 

  47. Amirikia KC, Mills P, Bush J, Newman LA (2011) Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer 117:2747–2753

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

TKW would like to thank Lundbeck Foundation and Danish Cancer Society for the support of this work. This study was supported by the State Committee for Scientific Research Grants: PBZ-KBN-042/P05/2001 and PBZ-KBN-122/P05/02

Conflict of interest

The authors declare that they have no conflict of interest

Author information

Authors and Affiliations

  1. Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland

    Satish Gupta, Katarzyna Jaworska-Bieniek, Jan Lubinski & Jakubowska Anna

  2. Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland

    Satish Gupta, Katarzyna Jaworska-Bieniek & Jan Lubinski

  3. Womens College Research Institute, University of Toronto, 790 Bay St, 7th Floor, Toronto, ON, M5G1N8, Canada

    Steven A. Narod

  4. Institute of Biomedicine, University of Aarhus, Århus, Denmark

    Tomasz K. Wojdacz

  5. Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden

    Tomasz K. Wojdacz

Authors
  1. Satish Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katarzyna Jaworska-Bieniek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven A. Narod
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan Lubinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomasz K. Wojdacz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jakubowska Anna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven A. Narod.

Additional information

Tomasz K. Wojdacz and Anna Jakubowska have contributed equally to the publication.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gupta, S., Jaworska-Bieniek, K., Narod, S.A. et al. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer. Breast Cancer Res Treat 148, 615–622 (2014). https://doi.org/10.1007/s10549-014-3179-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-014-3179-0

Keywords

Search

Navigation